Related Experiment Video
Updated: Oct 25, 2025

08:27
Detection of Human Leukocyte Antigen Biomarkers in Breast Cancer Utilizing Label-free Biosensor Technology
Published on: March 24, 2015
14.9K
State-of-the-art Hepatocellular Carcinoma Biomarker Detection by Biosensor Technology-a Review
1Faculty of Medicine, Department of Medical Biochemistry, Kafkas University, Kars, 36100, Turkey. onur_uygun@hotmail.com.
Journal of Gastrointestinal Cancer
|August 4, 2021
Summary
Biosensors offer promising self-diagnostic tools for early disease detection. This review compiles biosensor technologies for identifying hepatocellular carcinoma (HCC) biomarkers, enhancing clinical analysis.
Area of Science:
- Biomedical Engineering
- Analytical Chemistry
- Molecular Diagnostics
Background:
- Biosensors are increasingly vital for self-diagnostic technologies.
- Analyzing biomarkers with biosensor systems offers significant advantages in time, cost, and practicality.
- Early detection of challenging diseases like hepatocellular carcinoma (HCC) is crucial.
Purpose of the Study:
- To compile and review biosensor applications for hepatocellular carcinoma (HCC) biomarker determination.
- To highlight the potential of various biosensor platforms in clinical diagnostics.
Main Methods:
- Review of electrochemical, optical, and piezoelectric biosensors.
- Analysis of biosensors designed for protein, DNA, RNA, and cell detection.
- Examination of biorecognition elements including antibodies, DNA, aptamers, and nanocomposites.
Main Results:
- Various biosensor types are effective for detecting HCC biomarkers.
- Biosensors can be designed using diverse recognition elements like antibodies and aptamers.
- These technologies facilitate the analysis of biomarkers at varying concentrations.
Conclusions:
- Biosensors represent a powerful tool for the early detection and diagnosis of hepatocellular carcinoma.
- The development of advanced biosensor designs based on novel materials and recognition elements is ongoing.
- Biosensor technology holds significant promise for improving clinical studies and patient outcomes in HCC management.

